# MediLink Therapeutics (Suzhou) Co., Ltd. trials: 23 (2026)

ClinicalTrials.gov lists 23 trials with MediLink Therapeutics (Suzhou) Co., Ltd. as lead sponsor, 18 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by MediLink Therapeutics (Suzhou) Co., Ltd.: 23 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/medilink-therapeutics-suzhou-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 18
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 4, 2026 | NCT07803783 | A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure... | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 3 | Not yet recruiting | Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC) | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07803783) |
| July 31, 2026 | NCT07739758 | A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 3 | Recruiting | SCLC, Extensive Stage | 442 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739758) |
| March 23, 2026 | NCT07487896 | A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell... | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 3 | Recruiting | Advanced Esophageal Squamous Cell Carcinoma | 440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07487896) |
| March 10, 2026 | NCT07461454 | YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 3 | Recruiting | Locally Advanced or Metastatic Breast Cancer | 376 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07461454) |
| February 18, 2026 | NCT07416994 | Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous... | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 3 | Recruiting | Non-Small Cell Lung Cancer | 440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07416994) |
| February 12, 2026 | NCT07407933 | A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1/2 | Recruiting | Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07407933) |
| December 2, 2025 | NCT07258979 | A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1/2 | Recruiting | Recurrent or Metastatic Nasopharyngeal Carcinoma | 202 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07258979) |
| October 6, 2025 | NCT07208773 | A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1/2 | Recruiting | Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07208773) |
| October 1, 2025 | NCT07202364 | A Study of YL202 in Patients With Advanced Solid Tumors | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 2 | Recruiting | Non Small Cell Lung Cancer, Colorectal Cancer, Cervical Cancer, Locally Advanced or Metastatic Solid Tumors | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07202364) |
| September 29, 2025 | NCT07197827 | A Study of YL242 in Subjects With Advanced Solid Tumors | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 424 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07197827) |
| September 12, 2025 | NCT07169994 | A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1/2 | Recruiting | Advanced Solid Tumors, Breast Cancer, Non Small Cell Lung Cancer | 414 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07169994) |
| March 5, 2025 | NCT06859762 | A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1 | Recruiting | Advanced Solid Tumor | 630 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06859762) |
| October 8, 2024 | NCT06629597 | A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301) | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 3 | Active not recruiting | Nasopharyngeal Carcinoma | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06629597) |
| September 25, 2024 | NCT06612151 | A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302) | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 3 | Active not recruiting | Small Cell Lung Cancer | 438 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06612151) |
| June 14, 2024 | NCT06459973 | A Clinical Study of YL205 in Patients With Advanced Solid Tumors | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1/2 | Recruiting | Advanced Solid Tumors | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06459973) |
| June 3, 2024 | NCT06439771 | A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 2 | Recruiting | Locally Advanced or Metastatic Breast Cancer | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06439771) |
| May 1, 2024 | NCT06394414 | A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1 | Active not recruiting | Advanced Solid Tumors | 187 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06394414) |
| April 25, 2024 | NCT06384352 | Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1 | Recruiting | Advanced Solid Tumors | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06384352) |
| February 5, 2024 | NCT06241846 | A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 2 | Recruiting | Metastatic Castration-resistant Prostate Cancer (mCRPC) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06241846) |
| October 30, 2023 | NCT06107686 | A Study of YL202 in Selected Patients With Advanced Solid Tumors | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 2 | Recruiting | NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06107686) |
| September 28, 2023 | NCT06057922 | A Study YL201 in Patients With Selected Advanced Solid Tumors | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1/2 | Active not recruiting | Advanced Solid Tumor | 990 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06057922) |
| December 16, 2022 | NCT05653752 | A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1 | Active not recruiting | Non Small Cell Lung Cancer, Breast Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05653752) |
| June 27, 2022 | NCT05434234 | A Study of YL201 in Patients With Advanced Solid Tumors | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 312 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05434234) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 4 |
| Phase 1/2 | 8 |
| Phase 2 | 4 |
| Phase 3 | 7 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 17 |
| Active not recruiting | 5 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 5 |
| Breast Neoplasms | 5 |
| Small Cell Lung Carcinoma | 3 |
| Nasopharyngeal Carcinoma | 2 |
| Neoplasms | 1 |
| Pancreatic Neoplasms | 1 |
| Squamous Cell Carcinoma of Head and Neck | 1 |
| Colorectal Neoplasms | 1 |
| Uterine Cervical Neoplasms | 1 |
| Recurrence | 1 |
| Thoracic Neoplasms | 1 |
| Lung Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Barbecue restaurants in the United States](https://specstream.ai/data/businesses/barbecue-restaurants/united-states)
- [Marble and granite professional companies in the United States](https://specstream.ai/data/businesses/marble-and-granite-professional-companies/united-states)
- [Artificial turf companies in the United States](https://specstream.ai/data/businesses/artificial-turf-companies/united-states)
- [International fusion restaurants in the United States](https://specstream.ai/data/businesses/international-fusion-restaurants/united-states)
- [Welding supply stores in the United States](https://specstream.ai/data/businesses/welding-supply-stores/united-states)
- [Halal restaurants in the United States](https://specstream.ai/data/businesses/halal-restaurants/united-states)
